Ldl-cholesterol-lowering cell extract and food supplement

Abstract

An extract of Rhodospirillum rubrum includes rhodovibrin, 1-hydroxyspirilloxanthin, 3,4-didehydrorhodopin, chloroxanthin, bacteriopheophytin a, rhodopin, spirilloxanthin, 3,4-dihydrospirilloxanthin, phytyl derivative of bacteriopheophytin a, ubiquinol-10, ubiquinone-9, ubiquinone-10 and rhodoquinone-10. Such an extract could be used as a medicament, for lowering of LDL-cholesterol in blood plasma of a subject and/or for subjects who suffer from or have an increased risk of one or more of cardiovascular disease, atherosclerosis, dyslipidemia, arteriosclerosis, hypercholesterolemia, familial hypercholesterolemia, hyperlipidemia, an LDL plasma level of at least 70 mg/dL, a total cholesterol level of at least 200 mg/dL, an Lp(a) level of at least 14 mg/dL, inflammation, inflammatory disease, ischemia, or infection.

1 . An extract of  Rhodospirillum rubrum,  comprising rhodovibrin, 1-hydroxyspirilloxanthin, 3,4-didehydrorhodopin, chloroxanthin, bacteriopheophytin a, rhodopin, spirilloxanthin, 3,4-dihydrospirilloxanthin, phytyl derivative of bacteriopheophytin a, ubiquinol-10, ubiquinone-9, ubiquinone-10 and rhodoquinone-10. 
     
     
         2 . The petroleum ether extract of  Rhodospirillum rubrum  according to  claim 1 , for use as a medicament. 
     
     
         3 . The petroleum ether extract of  Rhodospirillum rubrum  according to  claim 1 , for use in the lowering of LDL-cholesterol in blood plasma of a subject. 
     
     
         4 . The petroleum ether extract of  Rhodospirillum rubrum  according to  claim 1 , for use in a method for the lowering of LDL-cholesterol in blood plasma of a subject. 
     
     
         5 . The petroleum ether extract of  Rhodospirillum rubrum  according to  claim 1 , for use in the lowering of LDL-cholesterol in blood plasma of a subject or for use in a method for the lowering of LDL-cholesterol in blood plasma of a subject, wherein the subject suffers from or has an increased risk for any one or more of cardiovascular disease, atherosclerosis, dyslipidemia, arteriosclerosis, hypercholesterolemia, familial hypercholesterolemia, hyperlipidemia, an LDL plasma level of at least 70 mg/dL, a total cholesterol level of at least 200 mg/dL, an Lp(a) level of at least 14 mg/dL, inflammation, inflammatory disease, ischemic, or infection. 
     
     
         6 . The petroleum ether extract of  Rhodospirillum rubrum  according to  claim 1 , wherein the extract is administered orally. 
     
     
         7 . A food supplement with LDL-cholesterol lowering properties, comprising the petroleum ether extract of  Rhodospirillum rubrum  according to  claim 1 . 
     
     
         8 . A foodstuff comprising the food supplement according to  claim 7 . 
     
     
         9 . A method for the production of the petroleum ether extract of  Rhodospirillum rubrum  of  claim 1 , comprising the steps of:
 a) providing  Rhodospirillum rubrum  cells   b) providing a biphasic mixture having about a 1:1 ratio by volume of petroleum ether that has a boiling point between 60° C. and 80° C. and methanol that comprises about 0.03% by weight of sodium chloride;   c) mixing the cells of step a) with the biphasic mixture of step b) for about 1 to 3 hours at a temperature between 15° C. and 25° C.;   d) separating the petroleum ether phase from the methanol phase of the biphasic mixture; and   e) isolating the petroleum ether phase, thereby obtaining the petroleum ether extract of  Rhodospirillum rubrum.      
     
     
         10 . A method of treating a subject in need thereof, the method comprising administering an extract of  Rhodospirillum rubrum , comprising rhodovibrin, 1-hydroxyspirilloxanthin, 3,4-didehydrorhodopin, chloroxanthin, bacteriopheophytin a, rhodopin, spirilloxanthin, 3,4-dihydrospirilloxanthin, phytyl derivative of bacteriopheophytin a, ubiquinol-10, ubiquinone-9, ubiquinone-10 and rhodoquinone-10. 
     
     
         11 . The method of  claim 10 , wherein the method lowers LDL-cholesterol in blood plasma of the subject. 
     
     
         12 . The method of  claim 10 , wherein the subject suffers from or has an increased risk for one or more of cardiovascular disease, atherosclerosis, dyslipidemia, arteriosclerosis, hypercholesterolemia, familial hypercholesterolemia, hyperlipidemia, an LDL plasma level of at least 70 mg/dL, a total cholesterol level of at least 200 mg/dL, an Lp(a) level of at least 14 mg/dL, inflammation, inflammatory disease, ischemia, or infection. 
     
     
         13 . The method of  claim 10 , wherein the method comprises administering the extract orally.